Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma-Reference-Cited by-同舟云学术

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Published:2017-11-28 Issue:2 Volume:180 Page:224-235
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Arcaini Luca¹²^ORCID,Lamy Thierry³,Walewski Jan⁴,Belada David⁵,Mayer Jiri⁶,Radford John⁷,Jurczak Wojciech⁸,Morschhauser Franck⁹,Alexeeva Julia¹⁰,Rule Simon¹¹^ORCID,Cabeçadas José¹²,Campo Elias¹³,Pileri Stefano A.¹⁴,Biyukov Tsvetan¹⁵,Patturajan Meera¹⁶,Casadebaig Bravo Marie-Laure¹⁵,Trnĕný Marek¹⁷,

Affiliation:

1. Department of Molecular Medicine; University of Pavia; Pavia Italy

2. Department of Haematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy

3. Department of Haematology; Hôpital Pontchaillou; Rennes France

4. Department of Lymphoid Malignancies; Maria Sklodowska-Curie Memorial Institute and Oncology Centre; Warsaw Poland

5. Fourth Department of Internal Medicine, Haematology; Charles University Hospital and Faculty of Medicine; Hradec Králové Czech Republic

6. Department of Internal Medicine, Haematology and Oncology; University Hospital Brno; Brno Czech Republic

7. The University of Manchester and the Christie NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester United Kingdom

8. Department of Haematology; Jagiellonian University Medical College; Kraków Poland

9. Department of Haematology; Hôpital Claude Huriez; EA 7365 GRITA; Lille France

10. Department of Haematology Research; Federal Medical Research Centre; Saint Petersburg Russia

11. Department of Haematology; Derriford Hospital; Plymouth United Kingdom

12. Serviço de Anatomia Patológica; Instituto Português de Oncologia de Lisboa Francisco Gentil; Lisboa Portugal

13. Haematopathology Unit, Hospital Clinic; University of Barcelona; Barcelona Spain

14. Unit of Haematopathology; European Institute of Oncology; Milan Italy

15. Clinical Research and Development; Celgene Sàrl; Boudry Switzerland

16. Clinical Research and Development; Celgene Corporation; Summit NJ USA

17. Department of Haematology; Charles University Hospital; Prague Czech Republic

Funder

Celgene

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15025/fullpdf

Reference15 articles.

1. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice;Avivi;Clinical Cancer Research,2015

2. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

3. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dreyling;Annals of Oncology,2014

4. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study;Dreyling;Lancet,2016

5. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study;Goy;Journal of Clinical Oncology,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects;Critical Reviews in Oncology/Hematology;2023-10

2. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-06

3. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England;Journal of Medical Economics;2022-06-06

4. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States;Journal of Medical Economics;2021-01-01

5. Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma;HemaSphere;2020-06